Comparative Pharmacology
Head-to-head clinical analysis: BETAPACE versus BETAXON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPACE versus BETAXON.
BETAPACE vs BETAXON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class III antiarrhythmic agent; prolongs cardiac action potential duration and refractory period by blocking potassium channels, primarily IKr.
Selective beta-1 adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production through inhibition of beta-1 receptors in the ciliary epithelium.
Oral: 80 mg twice daily; may increase up to 160 mg twice daily as needed.
0.25% ophthalmic solution, 1 drop in the affected eye(s) twice daily.
None Documented
None Documented
12 hours (10-20 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 36 hours).
Renal: >90% unchanged drug (sotalol) in urine; biliary/fecal: <10%
Primarily renal (40-50% unchanged) and fecal (30-40% as metabolites); biliary excretion contributes minimally.
Category C
Category C
Beta-Blocker
Beta-Blocker